CoreTissue BioEngineering, a pioneering Japanese medtech startup, has become the first company to join the R Accelerator Program. This initiative, supported by Mitsubishi Corporation Americas and Fogarty Innovation, is designed to help promising medtech companies from Japan navigate the U.S. market.
Innovation in ACL Reconstruction
CoreTissue BioEngineering is developing an artificial ligament derived from decellularized animal tissue. The solution aims to address the needs of over 800,000 patients globally who undergo anterior cruciate ligament (ACL) reconstruction surgery annually. The artificial ligament is designed to match the biocompatibility and strength of autologous transplants, eliminating the need for harvesting patient tissue.
Benefits of the Accelerator Program
The R Accelerator Program provides six months of comprehensive support, including business development plans, regulatory strategies, and reimbursement pathways. This support allows CoreTissue BioEngineering to leverage top-tier resources in Silicon Valley, enhancing their market entry strategy in the U.S. This program will also provide CoreTissue BioEngineering with valuable networking opportunities within the U.S. medtech ecosystem.
Mr. Shotaro Wakasa of Mitsubishi Corporation Americas shared his thoughts:
“Our goal is to support CoreTissue BioEngineering in expanding its reach and impact in the U.S. market.”
Mike Regan, Vice President of Strategy at Fogarty Innovation, added:
“We provide strategic and regulatory guidance to help promising medtech startups navigate the complex landscape of the U.S. healthcare market.”
Leadership with a Clear Vision
Under the leadership of CEO Chiaki Waki, CoreTissue BioEngineering is set to begin its pivotal clinical study in Japan later this year. With nearly two decades of experience in the medtech field, CEO Waki is focused on improving ACL reconstruction surgery and patient outcomes globally.
Japanese Medtech Startup, CoreTissue BioEngineering, Becomes First Company Accepted Into Accelerator Program Backed by Mitsubishi Corporation (Americas) and Fogarty Innovation https://t.co/D8JWC4Zp2k pic.twitter.com/RN1WClTMet
— Latest News from Business Wire (@NewsFromBW) July 29, 2024
What Are Your Thoughts?
CoreTissue BioEngineering’s entry into the R Accelerator Program marks a critical step in its journey towards transforming ACL reconstruction surgery. We encourage readers to share their thoughts and comments on this development and its potential impact on the medtech industry.
